Federal Regulatory Compliance Sample Clauses

Federal Regulatory Compliance a. In accordance with the federal regulatory requirement at 7 CFR § 251.2(d), the COUNTY agrees that – because it is allowed to further distribute PROGRAM COMMODITY and/or PROGRAM funds to other eligible recipient agencies (such as its designated Lead Agency) – the specific terms and conditions for doing so, including, if applicable, a list of specific organizations or types of organizations eligible to receive PROGRAM COMMODITY and/or PROGRAM funds, shall be identified either in the agreement with that eligible recipient agency or other written documents incorporated by reference into that agreement. b. In accordance with the federal regulatory provision at 7 CFR § 251.2(d)(1)(i), the COUNTY agrees that the COUNTY, its designated Lead Agency and any storage facility used for the handling, distribution or storage of PROGRAM COMMODITY will operate in accordance with the regulations at 7 CFR Part 250 and, as applicable, 7 CFR Part 251. c. In accordance with the federal regulatory provision at 7 CFR § 250.16 (a) the COUNTY agrees that the COUNTY and its designated Lead Agency are responsible to PDA for any improper distribution or use of PROGRAM COMMODITY or for any loss of (or damage to) PROGRAM COMMODITY caused by its fault or negligence.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Federal Regulatory Compliance a. In accordance with the federal regulatory requirement at 7 CFR § 251.2(d), the AGENCY agrees that – because it is allowed to further distribute PROGRAM COMMODITY to other eligible recipient agencies– the specific terms and conditions for doing so, including, if applicable, a list of specific organizations or types of organizations eligible to receive PROGRAM COMMODITY and/or PROGRAM funds, shall be identified either in the agreement with that eligible recipient agency or other written documents incorporated by reference into that agreement. b. In accordance with the federal regulatory provision at 7 CFR § 251.2(d)(1)(i), the AGENCY agrees that the AGENCY and any storage facility used for the handling, distribution or storage of PROGRAM COMMODITY will operate in accordance with the regulations at 7 CFR Part 250 and, as applicable, 7 CFR Part 251. c. In accordance with the federal regulatory provision at 7 CFR § 250.16 (a) the AGENCY agrees that it is responsible to PDA for any improper distribution or use of PROGRAM COMMODITY or for any loss of (or damage to) PROGRAM COMMODITY caused by its fault or negligence.
Sample 1Sample 2Sample 3See All (4)

Related to Federal Regulatory Compliance

  • Regulatory Compliance Neither Borrower nor any of its Subsidiaries is an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. Neither Borrower’s nor any of its Subsidiaries’ properties or assets has been used by Borrower or such Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted. None of Borrower, any of its Subsidiaries, or any of Borrower’s or its Subsidiaries’ Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!